Biosimilar and Biobetter Opportunity

Today I was listening to Podcast by Michael Kamarck President, Head Merck Bio ventures.......he said that at present Bio better and innovative drug have great future and that Merck in recent years has been keen in Bio better development and but in long run like all the big pharma Merck will venture in Bio similar's .......and already Merck in into two Bio similar product development.

 Later on he discussed about Merck pipeline , it already has Antibody in clinical trials for Solid tumours, two antibodies for Anti inflammatory for Phase 2....and now New Merck has many products in pipeline after last year M&A.........

Listen more at:http://biopharminternational.findpharma.com/biopharm/article/articleDetail.jsp?id=677150

FICCI- ABLE-Indian Biopharma- Update1

Last week on Monday July 12th I got invitation to attend National Biopharma convention organized by FICCI, ABLE in collaboration with government of India and Indian Biopharmaceutical companies.....

I am going to write the issues in Series so this is the first issue related to the points discussed over the conference.

According to Indian Bio pharma industry there were issues majorly related to
-Operational cost of running a bio pharmaceutical manufacturing plant
-Cost of the instruments and media related to biopharmaceutical development and production
-Involvement of more local players related to development and production of instruments, media and other lab requirements for Biopharma industry.
-Mr Sanjiv, VP product development from Cadila emphasized be one window concept which should be developed for regulatory approval
-Speakers also raised issues related to clinical trial development

India Biopharma Proposal

Currently India is a significant player in the global Biopharmaceutical Industry. To enhance its presence the Indian Industry and the Government need to join hands to address key issues and challenges to achieve and maintain a globally competitive and sustainable industry. FICCI has organized a one day national convention to offer platform to all stakeholders to identify areas where Industry needs facilitation and brainstorm with Government on how it can be done effectively. The conference deliberations will be an input to a Strategy paper being developed by Department of Pharmaceuticals for the Biopharma Industry. Key topics that the convention will cover include

· Manufacturing: Increasing Capacities and Efficiencies

·Infrastructure and HRD: Infrastructure for Product Development and Evaluation & Harnessing Indigenous Skills and addressing talent

·Challenges and Opportunities: Complexity in Development and Impact of Cost Constraint

·Regulations for Biopharma: Ensuring patient safety and enabling growth

The issues identified and discussed during this convention will be compiled and submitted to the Government for support and necessary action.

Next thing i wish pharma

Now a days after coming from office I have become addicted to How met you mother Series, last year this time I had finished sex and the city all seasons....thanks to my cousin in LA Manjul....for introducing me to Jimmy choo, Vogue .......and Carrie Bradshaw

Leaving apart my sense of fashion the following news headlines intrigued my brain

v     Sanofi going for $20 Billion deal in Biotechnology deal and like wise Lilly has also announced for more M&A this year

v     Abbott Laboratories is in market to sell its vaccines unit it gained after acquisition of Solvay Pharmaceuticals ($6.2bn)

v     Eli Lilly driving for enzyme replacement therapy (ERT) market and it is going to acquire of US based biotechnology firm Alnara Pharmaceuticals.

v     Some 5 years back Apt it acquired Quintiles pre clinical business and now Aptuit has again acquired GSK R&D unit in Italy....it’s a very good strategic expansion for a CRO which is majorly into preclinical studies.

After this news update what I am still awaiting for is the next biggest Bio similar deal in Indian peninsula